β-Erythroidin | 466-81-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: β-Erythroidin
• 英文别名: 6-Methoxy-1,4,6,10,12,13-hexahydro-3H,5H-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one；16-methoxy-5-oxa-10-azatetracyclo[8.7.0.01,13.02,7]heptadeca-2(7),12,14-trien-4-one
• CAS: 466-81-9
• 化学式: C₁₆H₁₉NO₃
• 分子量: 273.332
• InChiKey: PXWINCSLFXUWBZ-UHFFFAOYSA-N

物化性质

• 熔点：
  99.5-100°
• 比旋光度：
  D25 +88.8°
• 沸点：
  416.35°C (rough estimate)
• 密度：
  1.0888 (rough estimate)
• 溶解度：
  Water soluble

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Physical, chemical, and isotopic (atomic) labels
  申请人：Pearl Technology Holdings, LLC.

  公开号：US20040258617A1

  公开（公告）日：2004-12-23

  Chemical or isotopic labels are added to, e.g., a potentially lethal drug formulation, to generate a unique chemical fingerprint. Combinations of chemical additives are mixed with the drug to aid in their isolation and identification, especially when such drugs are used for illicit purposes. When stable isotopes are incorporated into lethal drugs, the labeling process conveys a very unique internal chemical signature and greatly aids in the identification of the parent drug in body fluids and tissues. When heath-care providers become aware that certain drugs can now be easily tracked and identified in a victim, individuals may be reluctant to utilize these agents for ill purposes.

  化学或同位素标记被添加到例如潜在致命的药物配方中，以生成独特的化学指纹。化学添加剂的组合与药物混合在一起，以帮助其隔离和识别，尤其是当这些药物被用于非法目的时。当稳定同位素被纳入致命药物中时，标记过程传达了非常独特的内部化学签名，并极大地帮助在体液和组织中识别母药。当医疗保健提供者意识到某些药物现在可以轻松跟踪和识别受害者时，个人可能会不愿意将这些药物用于不良目的。
• MRI-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening
  申请人：The Johns Hopkins University

  公开号：US10478120B2

  公开（公告）日：2019-11-19

  The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the blood-brain barrier (BBB) at an isolated region by locally administering an effective amount of a hyperosmolar agent at said region using a catheter, followed by administering a therapeutically effective amount of a therapeutic agent. The step of disrupting the BBB is carried out with non-invasive MR (magnetic resonance) imaging with a contrast agent to visualize local parenchymal transcatheter perfusion at said isolated BBB region thereby indicating that the BBB region is compromised. The method of the invention allows for highly precise drug delivery to the brain through blood brain barrier disruption at specifically controlled regions.

  本发明提供了一种通过血脑屏障受损区域直接向患有脑部疾病的受试者的脑实质施用治疗剂的方法，该方法包括首先通过使用导管在所述区域局部施用有效量的高渗剂来破坏隔离区域的血脑屏障（BBB），然后施用治疗有效量的治疗剂。破坏 BBB 的步骤通过使用造影剂的非侵入性 MR（磁共振）成像进行，以观察所述隔离 BBB 区域的局部实质经导管灌注，从而表明 BBB 区域受到破坏。本发明的方法可通过在特定受控区域破坏血脑屏障向大脑高度精确地输送药物。
• OCULAR GROWTH AND NICOTINIC ANTAGONISTS
  申请人：Valley Forge Pharmaceuticals, Inc.

  公开号：EP1272170A1

  公开（公告）日：2003-01-08
• PHARMACEUTICAL COMPOSITIONS CONTAINING ERYTHRINE MULUNGU DERIVATIVES AND PROCESSES FOR THEIR PRODUCTION
  申请人：Universidade Estadual Paulista Julio De Mesquita Filho-UNESP

  公开号：EP1948162B1

  公开（公告）日：2013-05-22
• Pharmaceutical Compositions Containing Erythrina Mulungu Derivatives, Processes for their Production and Uses Thereof
  申请人：Bolzani Vanderlan da silva

  公开号：US20080227801A1

  公开（公告）日：2008-09-18

  The present invention provides the use of molecules for cholinergic serotonergic and/or gabaergic system models, revealing pharmaceutical compositions comprising 11-OH-erythravine, erythravine, erythrartine, pharmaceutically acceptable isotherals, salts, byproducts and/or solvates thereof, optionally containing other Erythrine byproducts, for the treatment of anxiety disorders; processes for obtaining said pharmaceutical compositions are also revealed.